Summary
No substantive alignment can be verified because the provided FDA-approved prescribing information excerpt does not include the actual label text for indomethacin or the specific product’s full boxed warning; several brand-name and formulation/dosing-schedule claims are unsupported by the supplied labeling excerpt.
Category Scores
Accurate Statements
Indomethacin is an NSAID (nonsteroidal anti-inflammatory drug).
Not verifiable from the supplied boxed warning excerpt (which addresses NSAIDs generally, not indomethacin specifically).
Unsupported Statements
Common brand names for indomethacin include Indocin.
No brand-name information for indomethacin is present in the supplied FDA labeling excerpt.
Common brand names for indomethacin include Tivorbex.
No brand-name information for indomethacin is present in the supplied FDA labeling excerpt.
Indomethacin has multiple generic forms.
No information in the supplied FDA labeling excerpt addresses generic forms.
The generic active ingredient remains indomethacin.
No information in the supplied FDA labeling excerpt addresses generics/active ingredient identity.
Formulations of indomethacin can differ, including immediate-release versus other formulations.
No information in the supplied FDA labeling excerpt addresses formulation types (e.g., immediate-release).
Formulation differences can affect dosing schedules.
No information in the supplied FDA labeling excerpt addresses dosing schedules or how formulations change dosing.
Indomethacin is used for conditions involving pain and inflammation.
No indication information is included in the supplied FDA labeling excerpt.
Indomethacin is used for types of arthritis.
No indication information is included in the supplied FDA labeling excerpt.
Indomethacin is used for gout attacks.
No indication information is included in the supplied FDA labeling excerpt.
Contradictions
Low
AI Statement
Indomethacin is the generic name for indomethacin.
Label Reference
Not contradicted by the supplied boxed-warning excerpt; however, the statement is redundant/tautological and cannot be confirmed against the provided FDA-approved label excerpt.
Important Omissions
No attempt was made to support/align any statements with the provided FDA boxed warning text (cardiovascular risk) because the AI-generated statements do not reference the boxed warning content at all.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Claims about brand names, formulations, and dosing schedule implications are unsupported by the supplied FDA labeling excerpt, which limits confidence and could lead to misinterpretation of product-specific labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Insufficient and non-specific FDA label content was provided to verify most claims; multiple statements (brand names, generic/formulation, dosing schedule effects, and indications) are unsupported by the provided boxed-warning excerpt.
Suggested Improvement
Provide the complete FDA-approved indomethacin prescribing information (including Indications, Dosage and Administration, and any brand/formulation-specific sections), then restrict claims to statements explicitly supported by that label text.